High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4511-4515

  Miŕo, José M ^a,d   Entenza, José M ^b   Del Río, Ana ^a,d   Velasco, Maria ^c   Castañeda, Ximena ^a,d   De La Mària, Cristina Garcia ^a,e   Giddey, Marlyse ^b   Armero, Yolanda ^a,e   Pericàs, Juan M ^a,d   Cervera, Carlos ^a,d   Mestres, Carlos A ^a,f   Almela, Manuel ^a,e   Falces, Carlos ^a,f   Marco, Francesc ^a,e   Moreillon, Philippe ^b   Moreno, Asuncion ^a,d   Gatell, Jose M ^d   Jiménez De Anta, Maria T ^e   Paré, Juan C ^f   Cartañá, Ramón ^f   Ninot, Salvador ^f   Azqueta, Manel ^f   Sitges, Marta ^f   Heras, Magda ^f   Pomar, José L ^f   Ramírez, Jose ^g   Ribalta, Teresa ^g   Brunet, Merce ^h   Soy, Dolors ⁱ   Perez, Iñaki ^j   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d Infectious Diseases Service   (Spain)

^e Microbiology Service   (Spain)

^f Cardiovascular Institute   (Spain)

^g Pathology Department   (Spain)

^h Toxicology Service   (Spain)

ⁱ Pharmacy Service   (Spain)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; CASE REPORT; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; IN VITRO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; NATIVE VALVE ENDOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROSTHETIC AORTIC VALVE ENDOCARDITIS; PROSTHETIC VALVE ENDOCARDITIS; STAPHYLOCOCCAL ENDOCARDITIS; STAPHYLOCOCCUS INFECTION; THERAPY EFFECT;

AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; FEMALE; FOSFOMYCIN; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS;

EID: 84864383705     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06449-11     Document Type: Article

References (23)

1. Chen LY, et al. 2011. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect. Dis. 11:152.
2. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests; approved standard. Ninth edition. Clinical and Laboratory Standards Institute, Wayne PA.
3. Cubist Pharmaceuticals, Inc. 2010. Cubicin (daptomycin for injection) prescribing information. Cubist Pharmaceuticals, Inc., Lexington, MA.
4. Debbia E, Pesce A, Schito GC. 1988. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob. Agents Chemother. 32:279 -281.
5. Dengler V, Meier PS, Heusser R, Berger-Bächi B, McCallum N. 2011. Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in response to different cell wall active antibiotics. BMC Microbiol. 11:16.
6. Dhand A, et al. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
7. EuroSCORE. Accessed 15 October 2011. http://www.euroscore.org/. EuroSCORE, Cambridge, United Kingdom.
8. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. 2009. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin. Investig. Drugs 18:921-944.
9. Fowler VG, Jr, et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
10. Fowler VG, Jr, et al. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021.
11. Hendlin D, et al. 1969. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 166:122-123.
12. Isenberg HD. 2004. Time-kill assay, p 5.10.2.1-5.10.2.12. In H. D. Isenberg (ed), Clinical microbiology procedures handbook. ASM Press, Washington, DC.
13. Joukhadar C, et al. 2010. Bactericidal effects of fosfomycin against daptomycin resistant strains of Staphylococcus aureus, abstr. E-1573b. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
14. Levine DP, Lamp KC. 2007. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am. J. Med. 120(10 Suppl 1):S28-S33. (Pubitemid 47470058)
15. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
16. Mestres CA, et al. 2007. Preoperative risk stratification in infective endocarditis. Does the EuroSCORE model work? Preliminary results. Eur. J. Cardiothorac. Surg. 32:281-285. (Pubitemid 47021423)
17. Miró JM, et al. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514. (Pubitemid 41099645)
18. Miró JM, et al. 2009. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4172-4177.
19. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob. Agents Chemother. 52:980-990. (Pubitemid 351358377)
20. Pillai SK, Moellering RCJ, Eliopoulos GM. 2005. Antimicrobial combinations, p 365-440. In Lorian V (ed), Antibiotics in laboratory medicine, fifth edition. Lippincott Williams and Wilkins, Philadelphia, PA.
21. Popovic M, Steinort D, Pillai S, Joukhadar C. 2010. Fosfomycin: an old, new friend? Eur. J. Clin. Microbiol. Infect. Dis. 29:127-142.
22. Portier H, et al. 1985. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 13(Suppl 1):S123-S128.
23. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34:506-515.